Markets
markets
Luke Kawa

Bitcoin’s divorce from US tech stocks another damning sign of the “sell America” trade

It turns out Tyler Winklevoss wasn’t wrong. He was just early.

On the weekend following Liberation Day, the Gemini cofounder said that bitcoin’s resilience following an end-of-week meltdown in US stocks in response to Liberation Day indicated that bitcoin was “now behaving like a hedge to geopolitical uncertainty.”

The crypto asset promptly fell out of bed shortly following his remarks (womp womp!). But fast-forward a couple weeks and, well, you gotta hand it to him. Bitcoin has often behaved like a hyper-correlated, leveraged play on US tech stocks and recently, it hasn’t been trading like a US risk asset. It’s been trading without the taint of being associated with America — a characteristic that’s been damning for US stocks, government bonds, and the greenback.

Bitcoin’s has been an excellent store of value since April 2 (the last trading day prior to President Donald Trump’s reciprocal tariffs announcement in the Rose Garden). The digital currency is up about 2% over this time while the Nasdaq 100 is down nearly 9%. Not as good as gold, to be sure, but way better than the US dollar or long-term Treasury bonds, that’s for sure.

Most of the divergence is fairly recent, occurring in the past couple trading days as the “sell America” theme in financial markets has gone viral.

It’s a troubling sign, from the perspective of an owner of US assets, that the desire to sell America and own not-America appears to be playing a dominant role in driving price action across financial markets, overwhelming bitcoin’s traditional solid relationship with US tech stocks.

More Markets

See all Markets
markets

Lilly reports encouraging trial results for its next-gen GLP-1 shot

Eli Lilly released late-stage trial results for its next-generation GLP-1 shot, retatrutide, showing the drug helped patients lose more weight than anything currently on the market.

Patients taking the highest dose of retatrutide, 12 mg, lost 16.8% of their body weight after 40 weeks, more than its current best-seller, tirzepatide. The results also showed significant reduction in blood sugar levels.

The stock was flat in premarket trading following the news.

Lilly's tirzepatide, sold under the brand names Zepbound and Mounjaro, is currently the most-sold drug in the world. The company's sales have now outpaced its top-rival, Novo Nordisk, which was the first to bring a GLP-1 to market but has seen sales decelerate as competitors have muscled in.

Still, some expect Lilly's winning streak may not last forever. Analysts at HSBC gave the stock a rare downgrade earlier this week, citing a crowded market among other factors.

markets

Gold and silver dip amid inflation concerns and ongoing Iran war

Often seen as safe havens through times of uncertainty, precious metals aren't proving that way today, as oil prices spike amid escalations in the Iran war, compounding inflationary concerns and sending the SPDR Gold Shares ETF and iShares Silver Trust down 3.4% and 6.6%, respectively, at 6:55 a.m. ET.

Although the Fed kept rates steady yesterday, as was universally expected, officials raised their forecasts for inflation — a move which seems to have spooked investors, who had already been taking risk off the table in recent weeks. With Brent crude north of $114 per barrel this morning, investors look to be bracing for further inflationary shock and are dumping gold and silver, as implied odds of a Fed rate cut in June plummeted on prediction markets from 60% on February 23rd, to just 16% this morning.

The shiny metal slump is already weighing on mining stocks like Anglogold Ashanti, Newmont, Wheaton Precious Metals, and Agnico Eagle, which are all plunging in premarket trading.

Dickens, Great Expectations, and lay on the floor

Micron blew the lights out on earnings, so why is the stock dropping?

After a relentless rise into the print, a stunning beat — 21% on revenue and 36% on adjusted EPS — wasn't quite enough to keep the momentum going.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.